In the context of human cancers where the BIM deletion allele predicts poorer therapeutic responses and clinical outcomes, such as in CML or EGFR-NSCLC, the splice-switching ASOs we have identified may be used in combination with appropriate TKIs to overcome the negative effects of the BIM deletion. The gene discussed is BCL2L11; the disease is non-small cell lung carcinoma.